Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis.
GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR). In this phase 2, double-blind, parallel-group study, patients (≥12 years of age) with SAR were equally randomized to twice-daily GSP301 (olopatadine 665μg and mometasone 25μg), once-daily GSP301 (olopatadine 665μg and mometasone 50μg), twice-daily or once-daily olopatadine monotherapy (665μg), mometasone monotherapy (twice-daily 25μg or once-daily 50μg), or placebo for 14 days. The primary endpoint-mean change from baseline in morning and evening reflective Total Nasal Symptom Score (rTNSS)-was analyzed using ANCOVA (P<0.05=statistically significant). Average morning and evening 12-hour instantaneous TNSS (iTNSS), ocular symptoms, individual symptoms, onset of action, quality of life, and adverse events (AEs) were also assessed. A total of 1,111 patients were randomized. Twice-daily GSP301 provided statistically significant and clinically meaningful rTNSS improvements versus placebo (P<0.001), twice-daily olopatadine (P=0.049) and mometasone (P=0.004). Similar significant improvements in iTNSS were observed with twice-daily GSP301 versus placebo (P<0.001) and twice-daily mometasone (P=0.007); improvements were not significant versus olopatadine (P=0.058). Once-daily GSP301 provided significant rTNSS and iTNSS improvements versus placebo and once-daily olopatadine (P<0.01, all) but improvements were not significant versus mometasone. Treatment-emergent AEs rates were 10.8%, 9.5%, and 8.2%, with twice-daily GSP301, once-daily GSP301, and placebo, respectively. Twice-daily GSP301 treatment was efficacious and well tolerated, providing statistically significant and clinically meaningful improvements in rTNSS (primary endpoint) versus placebo and both monotherapies.